A Bartlett

Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

Critical Comparison of Novel and Existing Methods of Compliance Assessment During a Clinical Trial of an Oral Iron Chelator

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

The β-Thalassemias

Advances in metal-induced oxidative stress and human disease

Antiproliferative and Apoptotic Effects of Iron Chelators on Human Cervical Carcinoma Cells

Liver iron depletion and toxicity of the iron chelator Deferiprone (L, CP20) in the guinea pig

A systematic review of the associations between dose regimens and medication compliance

Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications

A Risk-Benefit Assessment of Iron-Chelation Therapy

Stroke in Children With Sickle Cell Anaemia

Drug glucuronidation in humans

Pharmacokinetics of Oxicam Nonsteroidal Anti-Inflammatory Agents

Cyclodextrin-based pharmaceutics: past, present and future

Global epidemiology of haemoglobin disorders and derived service indicators

5 Thalassaemia: clinical management

Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major

Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi

Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major

Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species

Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin

Moyamoya Disease and Moyamoya Syndrome

Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness

Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: Comparison of their mechanism of protection with that of desferrioxamine

Heavy metal induced oxidative stress & its possible reversal by chelation therapy.

Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo

Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease

Principles and Recent Developments in Chelation Treatment of Metal Intoxication

Role of deferiprone in chelation therapy for transfusional iron overload

Iron-Chelating Therapy and the Treatment of Thalassemia

Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients

Long‐term trial with the oral iron chelator 1,2‐dimethy1‐3‐hydroxypyrid‐4‐one (L₁) II. CLINICAL OBSERVATIONS

Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers

Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one

Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L₁) I. IRON CHELATION AND METABOLIC STUDIES

The Effect of Antacid and Ranitidine on Droxicam Pharmacokinetics

Comparative study of the multiple dose pharmacokinetics and the tolerance of a new NSAID (droxicam) versus piroxicam in healthy volunteers.